Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, RNAi Consortium Validating Clones for Second Phase of Effort

This article has been updated from a previous version to clarify Sigma-Aldrich's role in the validation process. 
 
NEW YORK (GenomeWeb News) - Sigma-Aldrich said today that it is working with the RNAi Consortium to functionally validate around 160,000 previously cloned, lentiviral-based shRNA vector constructs as part the second phase of the project.
 
The company said that so far more than 5,000 clones have been tested in the functional validation process.
 
“Validated clones covering more than 700 genes are available in Sigma-Aldrich's Mission shRNA collection, a number expected to grow by 75,000 clones per year through 2011,” Sigma-Aldrich said in a statement.
 
The company added that the consortium intends to generate and validate 150,000 additional clones to help develop new RNAi screening approaches.
 
The RNAi Consortium was established by the Broad Institute in 2004. The public/private alliance of RNAi researchers is developing genome-scale sets of virally expressed shRNAs targeting mouse and human genes.
 
A “key goal” of the consortium is to provide at least two clones with a knockdown level of 70 percent or greater for every human and mouse gene over the next four years, the company said.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.